How changes in immune cells affect asthma development
Metabolic perturbations in conventional dendritic cells modulate Tfh13 induction in asthmatic sensitization
This study is looking at how changes in certain immune cells can affect the way your body responds to allergens, which might help us find new treatments for allergic asthma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10984961 on NIH RePORTER |
What this research studies
This research investigates how metabolic changes in dendritic cells, a type of immune cell, influence the development of T follicular helper 13 cells, which are crucial for producing IgE antibodies that trigger allergic asthma. By examining the effects of allergens on dendritic cells, the study aims to uncover the mechanisms that lead to asthma sensitization. The researchers will analyze how these immune cells metabolize nutrients like glutamine in response to allergens and how this affects their ability to induce Tfh13 cells. Ultimately, the goal is to translate these findings into potential new treatments for allergic asthma.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with allergic asthma or those who are at risk of developing asthma due to environmental allergens.
Not a fit: Patients with non-allergic asthma or those whose asthma is not influenced by environmental allergens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that better manage or prevent allergic asthma.
How similar studies have performed: Previous research has shown that targeting metabolic pathways in immune cells can lead to significant advancements in understanding and treating allergic conditions, suggesting that this approach may yield promising results.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Martin, Rebecca Kelley — Virginia Commonwealth University
- Study coordinator: Martin, Rebecca Kelley
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.